Clinical management of arthralgia and bone health in women undergoing adjuvant aromatase inhibitor therapy

Current Opinion in Oncology

Volumn 19, Issue SUPPL. 1, 2007, Pages

  Thorne, Carter ^a  

^a SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

Author keywords

Aromatase inhibitors; Arthralgia; Bisphosphonates; Bone mineral density; Breast cancer; Dual X ray absorptiometry scanning; Fracture; Osteopenia; Osteoporosis

Indexed keywords

ALENDRONIC ACID; AMFEBUTAMONE; ANASTROZOLE; CALCIUM; CAPSAICIN; CHONDROITIN SULFATE; EXEMESTANE; FLUOXETINE; GLUCOSAMINE; HEPATITIS B VACCINE; IBANDRONIC ACID; ISONIAZID; LANSOPRAZOLE; LETROZOLE; MENINGITIS VACCINE; MIRTAZAPINE; NAPROXEN; OPIATE; PARACETAMOL; PLACEBO; PROCAINAMIDE; QUINIDINE; QUINOLONE; RISEDRONIC ACID; SALICYLIC ACID METHYL ESTER; TAMOXIFEN; TERBINAFINE; TRAMADOL; UNINDEXED DRUG; VITAMIN D;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALCOHOL CONSUMPTION; ARTHRALGIA; BONE DEMINERALIZATION; BONE DENSITOMETRY; BONE DENSITY; BONE FRAGILITY; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGUS ULCER; FRACTURE; FRAGILITY FRACTURE; HUMAN; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LOOSE FECES; LUPUS LIKE SYNDROME; MUSCLE EXERCISE; MUSCLE STRENGTH; MYALGIA; NAUSEA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 34248192300     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000266467.69821.2a     Document Type: Review

References (69)

1. Goss P, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19:881-894.
2. Morales L, Neven P, Paridaens R. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 2005; 17:559-565.
3. Kaufmann M, Jonat W, Hilfrich J, et al. Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study [poster]. In: American Society of Clinical Oncology meeting. Atlanta, GA, 2-6 June 2006.
4. Coombes RC, Paridaens R, Jassem J, et al., for the Intergroup Exemestane Study (IES). First mature analysis of the Intergroup Exemestane Study [Abstract LBA527]. J Clin Oncol 2006; 24:18S.
5. Theriault RL, Biermann JS, Brown E, et al. NCCN Task Force Report: Bone health and cancer care. J Natl Compr Canc Netw 2006; 4 (Suppl. 2):S1-S20.
6. Winer E, Hudis C, Burstein H, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-629.
7. Eisen A, Trudeau M, Shelley W, Sinclair S, and the Breast Cancer Disease Site Group. The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: a clinical practice guideline. Evidence-based series no. 1-18. Toronto: Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO); October 2005.
8. Coombes R, Hall E, Gibson L, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092.
9. Goss P. Breast cancer prevention - clinical trials strategies involving aromatase inhibitors. J Steroid Bioch Mol Biol 2003; 86:487-493.
10. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. J Natl Cancer Inst 2005; 97:1262-1271.
11. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
12. Lentle B, Prior J. Osteoporosis: what a clinician expects to learn from a patient's bone density examination. Radiology 2003; 228:620-628.
13. Bingefors K, Isacson D. Epidemiology, co-morbidity, and impact on healthrelated quality of life of self-reported headache and musculoskeletal pain - a gender perspective. Eur J Pain 2004; 8:435-450.
14. Xu J, Bartoces M, Neale A, et al. Natural history of menopause symptoms in primary care patients: a MetroNet study. J Am Board Fam Pract 2005; 18:374-382.
15. Reed P. Arthralgia. The medical disability advisor, 2005. Available at: www.rgl.net. Accessed: February 2007.
16. West Midlands Centre for Adverse Drug Reaction Reporting. Drug-induced muscle and joint pain, 2003. Available at: http://www.csmwm.org. Accessed: February 2007.
17. Kim MJ, Ye YM, Park HS, Suh CH. Chemotherapy-related arthropathy. J Rheumatol 2006; 33:1364-1368.
18. Donnellan P, Douglas S, Cameron D, et al. Aromatase inhibitors and arthralgia. J Clin Oncol 2001; 19:2767.
19. Buzdar AU. Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial [poster]. In: American Society of Clinical Oncology meeting. Atlanta, GA, 2-6 June 2006.
20. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2006; 11 December E-pub ahead of print.
21. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer 2005; 93 (Suppl. 1):S16-S22.
22. Lonning P, Geisler J, Krag L, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23:5126-5137.
23. McCloskey E, Hannon R, Lakner G, et al. The letrozole, exemestane, and anastrozole pharmacodynamics (LEAP) trial: a direct comparison of bone biochemical measurements between aromatase inhibitors in healthy postmenopausal women [poster]. In: American Society of Clinical Oncology meeting. Atlanta, GA, 2-6 June 2006.
24. Banerjee S, Smith I, Folkerd L, et al. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol 2005; 16:1632-1638.
25. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006; 20:1029-1039.
26. Lipton A, Alvarado C, DeBoer R, et al. Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with IV bisphosphonates [Abstract 512]. J Clin Oncol 2006; 24 (Suppl. 18S):6s.
27. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC, National Osteoporosis Foundation, 2003. Available at: http://www.nof.org. Accessed: February 2007
28. Mackey J, Joy A. Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer 2005; 114:1010-1015.
29. Miller J, Lee S. Radiology rounds. A newsletter for referring physicians. Massachusetts General Hospital Department of Radiology, 2005. Available at: http://www.massgeneralimaging.org/newsletter/august_2005/august_2005.pdf. Accessed: February 2007.
30. Brown J, Josse R. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002; 167 (10 Suppl):S1-S34.
31. National Osteoporosis Foundation. Rehabilitation of patients with osteoporosis-related fractures. Osteoporosis Clinical Updates, 2003 iv. Available at: http://www.nof.org/cmeexam/Issue5Rehab/RehabWebversion.pdf. Accessed: February 2007.
32. US Department of health and human services (USDHHS). Bone health and osteoporosis. A report of the surgeon general 2004. Available at: http:// www.surgeongeneral.gov/library. Accessed: February 2007.
33. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999; 14:1614-1621.
34. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531-1538.
35. National Institutes of Health. Osteoporosis and related bone diseases - National Resource Center. Osteoporosis: coping with chronic pain. Available at: http://www.niams.nih.gov/bone/hi/osteoporosis_pain.htm.March 2005. Accessed: March 2007
36. Plourde P. Arthralgia in postmenopausal breast cancer patients on adjuvant endocrine therapy: a risk-benefit analysis [Poster]. Lynn Sage Breast Cancer Symposium, 2005. Chicago, IL, October 10, 2005.
37. Evans D, Charney D, Lewis L. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 58:175-189.
38. Warr D, Johnston M, and members of the Breast Cancer Disease Site Group. Use of bisphosphonates in women with breast cancer. Practice guideline report no. 1-11. Toronto: Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO); April 2004.
39. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; 3:CD003474.
40. Adami S, Fossaluzza V, Gatti D, et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome: pharmacologic management in the patient with bone metastasis. Ann Rheum Dis 1997; 56:201-204.
41. Robinson J, Sandom J, Chapman P. Efficacy of pamidronate in complex regional pain syndrome type I. Pain Med 2004; 5:276-280.
42. Manicourt DH, Brasseur JP, Boutsen Y, et al. Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum 2004; 50:3690-3697.
43. Boonen S, Haentjens P, Vandenput L, et al. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med 2004; 255:1-12.
44. Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol Suppl 2002; 66:3-8.
45. Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev 2006; 15:1427-1437.
46. Eriksen E, Glerup H. Vitamin D deficiency and aging: implications for general health and osteoporosis. Biogerontology 2002; 3:73-77.
47. US Department of Health and Human Services (USDHHS). Physical activity and health. A report of the surgeon general 1996. Available at: http://www.cdc.gov/nccdphp/sgr/pdf/execsumm.pdf. Accessed: February 2007.
48. National Institutes of Health. Osteoporosis and related bone diseases - National Resource Center. Exercise for your bone health, 2005. Available at: http://www.niams.nih.gov/bone/hi/bone_exercise.pdf. Accessed: February 2007.
49. Hillner B, Ingle J, Chlebowski R, et al. Update on the role of bisphosphonates and bone health issues in women with breast cancer. American Society of Clinical Oncology. J Clin Oncol 2003; 21:4042-4057.
50. Fosamax (alendronate sodium) tablet and oral solution, prescribing information. Whitehouse Station, NJ: Merck and Co., Inc.; 2006.
51. Actonel (risedronate sodium) tablets, prescribing information. Cincinnati, OH: Proctor and Gamble Pharmaceuticals Inc.; 2006.
52. Boniva (ibandronate sodium) tablets, prescribing information. Nutley, NJ: Roche Laboratories Inc.; 2006.
53. Didronel (etidronate sodium) prescribing information. Cincinnati, OH: Proctor and Gamble Pharmaceuticals Inc.; 2005.
54. Zometa (zoledronic acid) injection, prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2005.
55. Aredia (pamidronate disodium) injection, prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2006.
56. Miacalcin (calcitonin-salmon) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2006.
57. Calcimar (calcitonin-salmon) prescribing information. Montreal, QC: Sanofi-Aventis; 2006.
58. Black DM, Cummings SR, Karpf DB, et al. Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535-1541.
59. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures results from the Fracture Intervention Trial. JAMA 1998; 280:2077-2082.
60. Gnant M, Jakesz R,Mlineritsch B, et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12). In: San Antonio Breast Cancer Symposium. San Antonio, TX, 8 December 2004 [Abstract 6].
61. Woo SB, Hellstein JW, Kalmar JR. Narrative (corrected) review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753-761.
62. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567-1575.
63. Chesnut C, Majumdar S, Newitt D, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res 2005; 20:1548-1561.
64. Ofluoglu D, Akyuz G, Unay O, et al. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol 2006; E-pub ahead of print.
65. ClinicalTrials.gov. Monash University, May 2005. Changes in knee articular cartilage volume in women on aromatase inhibitors. Available at: http://clinicaltrials.gov/ct/show/NCT00111241. Accessed: February 2007.
66. ClinicalTrials.gov. A trial of high dose vitamin d therapy on musculoskeletal symptoms and bone mineral density in anastrozole-treated early stage breast cancer patients with marginal vitamin D status. Washington University School of Medicine and Astrazeneca, September 2006. Available at: http://clinicaltrials.gov/ct/show/NCT00263185. Accessed: February 2007.
67. Compston J. Current and emerging therapies for the treatment of postmenopausal osteoporosis. Business briefing: European pharmacotherapy; London, UK: Touch Briefings; 2006. pp. 73-76.
68. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350:459-468.
69. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90:2816-2822.